Verrica Shares Soar 33% on $50M Financing and Caligan’s 9.99% Stake

Introduction

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is a dermatology therapeutics company headquartered in West Chester, Pennsylvania. Founded in 2013, Verrica develops and commercializes topical treatments for viral and oncologic skin diseases. As of November 28, 2025, its shares traded at $8.9152—an increase of 32.86% with a trading volume of 632,556.

Corporate Structure

Verrica employs approximately 51–200 people across clinical development, sales, marketing, manufacturing, and administration. The company’s leadership team has extensive pharmaceutical experience, having collectively launched over 50 products. Verrica fosters a collaborative culture that enables employees to contribute to innovation and operational efficiency.

Dermatology by karelys Ruiz

Recent Developments

On November 24, 2025, Caligan Partners LP filed a Schedule 13D disclosing the acquisition of 6,503,054 shares—approximately 9.99% of Verrica’s outstanding stock—with shared voting and dispositive power, along with the right to designate a board member. Earlier, on November 14, 2025, Armistice Capital LLC and Steven Boyd amended a Schedule 13G/A to report ownership of 639,193 shares (6.77%) as of September 30, 2025.

Also on November 24, Verrica announced a $50 million private placement financing led by Caligan Partners LP and PBM Capital. Proceeds from this financing will be used to retire the debt facility from OrbiMed and extend the company's cash runway into mid-2027.

Between November 5 and 9, 2025, Verrica presented Phase 2 data on VP-315 at the 40th Society for Immunotherapy of Cancer Annual Meeting. The exploratory analyses indicated a 97% objective response rate and a 51% complete histologic clearance in patients with basal cell carcinoma, supporting evidence of tumor microenvironment changes.

Verrica’s development partner Torii received regulatory approval for YCANTH® in Japan, expanding patient accessibility beyond the United States. Additionally, the company announced plans for a global Phase 3 program for YCANTH in common warts, which are a prevalent skin condition.

Financial and Strategic Analysis

The $50 million financing will retire Verrica’s OrbiMed debt facility and provide operational funding through mid-2027. This financing aims to reduce financial leverage and support the commercialization of YCANTH (cantharidin topical solution 0.7%) for molluscum contagiosum. The liquidity boost will facilitate ongoing clinical programs, particularly the VP-315 oncolytic peptide for basal and squamous cell carcinoma under a worldwide license agreement with Lytix Biopharma AS.

The changes in ownership reported in SEC filings suggest that Caligan Partners LP may influence corporate governance, while Armistice Capital’s stake indicates continued institutional interest in the company. The increase in stock price and trading volume on November 28 aligns with investor reactions to the financing announcement and potential board representation.

Market Position and Industry Context

Verrica operates in the dermatology and pediatric dermatology sectors, focusing on skin conditions with limited treatment options. Its lead product, YCANTH, received FDA approval on July 21, 2023, for the treatment of molluscum contagiosum in patients aged two and older—a condition affecting an estimated six million individuals annually in the U.S. The product pipeline also includes VP-102 for common warts and VP-315 for non-melanoma skin cancers. Progress in ongoing clinical trials and regulatory approvals will impact Verrica’s competitive positioning within both topical therapies and emerging immunotherapeutics.

TL;DR

On November 24, 2025, Verrica Pharmaceuticals closed a $50 million private placement financing—anchored by Caligan Partners LP and PBM Capital—to retire existing debt and fund operations through mid-2027. Caligan Partners disclosed a 9.99% stake (Schedule 13D), gaining rights to designate a board member; Armistice Capital holds 6.77% (Schedule 13G/A). Phase 2 data for VP-315 presented November 5–9 indicated a 97% objective response rate and a 51% complete clearance in basal cell carcinoma. Regulatory approval for YCANTH in Japan was confirmed, and a global Phase 3 trial for common warts is in progress. Stock (VRCA) traded at $8.9152, reflecting a 32.86% increase. Future catalysts include the commercialization of YCANTH, results from the common warts trial, and the integration of new board representation.